Vaccine and Clinical Trials

rDNA technology in vaccine development

In order to create a new genetic sequence that may be introduced into host cells (such as bacteria, yeast, or mammalian cells) to make particular proteins—typically antigens used in vaccines—recombinant DNA (rDNA) technology combines DNA from several organisms. This method, which is fundamental to contemporary biotechnology, enables researchers to develop tailored, safe, and efficient vaccinations without utilizing whole pathogens.

Recent Developments (2023–2025)

 Recent vaccine technology advancements use recombinant DNA methods to create targeted, effective vaccines against challenging diseases. For malaria, R21/Matrix-M fused CSP with Hepatitis B virus surface antigen. For influenza, researchers are developing a universal flu vaccine using conserved regions of hemagglutinin stem protein. Next-generation HPV vaccines target a wider range.